LexDanaLexDanabeta
Inventor

Jun Feng

Inventor
San Diego, CA, US

Overview

69→
Patents
2003–2021
Patent span
Human necessities
Primary field (CPC A)

Patents· 69 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

C07Dprimary
C07DHeterocyclic compounds38%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations36%
A61KPreparations for medical, dental or toiletry purposes14%
G01NInvestigating or analysing materials by determining their chemical or physical properties4%
C07BGeneral methods of organic chemistry3%
C07CAcyclic or carbocyclic compounds2%
C07FAcyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium2%
C07KPeptides1%
C11DDetergent compositions1%
C12NMicroorganisms or enzymes1%
PatentTitleYear
11,028,080Substituted pyrimidines as LRKK2 inhibitors202110,975,071Inhibitors of KRAS G12C mutant proteins202110,927,125Substituted cinnolines as inhibitors of KRAS G12C202110,919,850Covalent inhibitors of KRas G12C202110,882,847Inhibitors of KRAS G12C mutant proteins202110,875,842Inhibitors of KRAS G12C mutant proteins202010,858,343Inhibitors of KRAS G12C mutant proteins202010,829,458Substituted quinazoline compounds and methods of use thereof202010,822,312Substituted quinazoline compounds and methods of use202010,745,385Covalent inhibitors of KRAS202010,736,897Compounds and methods of use thereof for treatment of cancer202010,730,867Inhibitors of KRAS G12C mutant proteins202010,723,738Inhibitors of KRAS G12C mutant proteins202010,689,356Inhibitors of KRAS G12C mutant proteins202010,647,703Inhibitors of KRAS G12C mutant proteins202010,588,907Methods and compositions for inhibiting the interaction of menin with MLL proteins202010,428,064Fused-tricyclic inhibitors of KRAS and methods of use thereof201910,414,7572-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof201910,377,743Inhibitors of RAS and methods of use thereof201910,370,386Substituted quinolines as inhibitors of KRAS G12C201910,351,550Substituted quinazoline compounds and methods of use thereof201910,301,317Inhibitors of ERK and methods of use201910,280,172Inhibitors of KRAS G12C mutant proteins201910,273,207Covalent inhibitors of kras G12C201910,246,424Substituted quinazoline compounds and methods of use thereof201910,246,464Thienopyrimidine and thienopyridine compounds and methods of use thereof201910,174,041Methods and compositions for inhibiting the interaction of menin with MLL proteins201910,144,724Substituted quinazoline compounds and methods of use thereof201810,077,271Methods and compositions for inhibiting the interaction of menin with MLL proteins201810,011,600Methods and compositions for inhibition of Ras20189,951,078Inhibitors of ERK and methods of use20189,926,267'Covalent inhibitors of K-Ras G12C'20189,862,701'Inhibitors of KRAS G12C mutant proteins'20189,840,516'Substituted quinazolines as inhibitors of KRAS G12C'20179,745,319'Irreversible covalent inhibitors of the GTPase K-Ras G12C'20179,624,228'Inhibitors of ERK and methods of use'20179,434,743'Indazole derivatives'20169,227,978'Covalent inhibitors of Kras G12C'20168,871,774'Inhibitors of influenza viruses replication'20148,530,499'Glucokinase activators'20138,394,843'Substituted isoindoles as glucokinase activators'20138,329,900'Dipeptidyl peptidase inhibitors'20128,288,539'Dipeptidyl peptidase inhibitors'20128,222,411'Dipeptidyl peptidase inhibitors'20128,188,275'Dipeptidyl peptidase inhibitors'20128,173,663'Dipeptidyl peptidase inhibitors'20128,173,645'Glucokinase activators'20128,163,779'Glucokinase activators'20128,093,382'Dipeptidyl peptidase inhibitors'20128,034,822'Glucokinase activators'20118,008,332'Substituted indazoles as glucokinase activators'20117,960,384'Dipeptidyl peptidase inhibitors'20117,906,523'Dipeptidyl peptidase inhibitors'20117,872,124'Dipeptidyl peptidase inhibitors'20117,825,242'Dipeptidyl peptidase inhibitors'20107,795,428'Dipeptidyl peptidase inhibitors'20107,790,736'Dipeptidyl peptidase inhibitors'20107,790,734'Dipeptidyl peptidase inhibitors'20107,781,584'Dipeptidyl peptidase inhibitors'20107,723,344'Dipeptidyl peptidase inhibitors'20107,687,638'Dipeptidyl peptidase inhibitors'20107,687,625'Dipeptidyl peptidase inhibitors'20107,638,638'Dipeptidyl peptidase inhibitors'20097,579,357'Dipeptidyl peptidase inhibitors'20097,550,590'Dipeptidyl peptidase inhibitors'20097,470,700'Dipeptidyl peptidase inhibitors'20086,903,132'Non-peptide GnRH agents, pharmaceutical compositions and methods for their use'20056,833,372'Non-peptide GnRH agents, Pharmaceutical compositions, and methods for their use'20046,613,942'Glucagon antagonists/inverse agonists'2003

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

2004–2013Based in Carlsbad, CA, US· patent location history
2008–2012Patents assigned to TAKEDA PHARMACEUTICAL (18)· patent assignee history
2009–2013Patents assigned to TAKEDA SAN DIEGO INC (8)· patent assignee history
2012–2013Patents assigned to FENG JUN (10)· patent assignee history
2012–2013Patents assigned to GWALTNEY STEPHEN L (10)· patent assignee history
2012–2021Based in San Diego, CA, US· patent location history
2014Based in Acton, MA, US· patent location history
2016–2021Patents assigned to ARAXES PHARMA LLC (29)· patent assignee history
2019Based in La Jolla, CA, US· patent location history
2021Based in San Mateo, CA, US· patent location history

Inventor activity

Assignee and location history derived from the patent record.

Assignees
AssigneePatentsSpan
ARAXES PHARMA LLC292016–2021
TAKEDA PHARMACEUTICAL182008–2012
FENG JUNself102012–2013
GWALTNEY STEPHEN L102012–2013
TAKEDA SAN DIEGO INC82009–2013
Locations
LocationPatentsSpan
San Diego, California, US382012–2021
Carlsbad, California, US272004–2013
San Mateo, California, US12021
La Jolla, California, US12019
Acton, Massachusetts, US12014